Abstract

It has been proposed that a subpopulation of tumour cells with stem cell-like characteristics, known as cancer stem cells (CSCs), drives tumour initiation and generates tumour heterogeneity, thus leading to cancer metastasis, recurrence, and drug resistance. Although there has been substantial progress in CSC research into many solid tumour types, an understanding of the biology of CSCs in lung cancer remains elusive, mainly because of their heterogeneous origins and high plasticity. Here, we demonstrate that engineered lung cancer cells derived from normal human airway basal epithelial cells possessed CSC-like characteristics in terms of multilineage differentiation potential and strong tumour-initiating ability. Moreover, we established an in vitro 3D culture system that allowed the in vivo differentiation process of the CSC-like cells to be recapitulated. This engineered CSC model provides valuable opportunities for studying the biology of CSCs and for exploring and evaluating novel therapeutic approaches and targets in lung CSCs.

Highlights

  • Lung cancer is the leading cause of cancer-related mortality, resulting in more than one million deaths worldwide annually [1]

  • Using Non-small-cell lung cancer (NSCLC) cell lines and patient-derived primary adenocarcinoma cells, Akunuru et al reported that cancer stem cells (CSCs) were enriched in multiple phenotypically distinct subpopulations [20]

  • Considering the inconsistencies in the markers identified for lung CSCs, it is preferable to define CSCs based on their biological functions

Read more

Summary

Introduction

Lung cancer is the leading cause of cancer-related mortality, resulting in more than one million deaths worldwide annually [1]. Non-small-cell lung cancer (NSCLC), of which adenocarcinoma is the most common histological subtype, accounts for approximately 80% of all lung cancer cases and is often diagnosed at an advanced, inoperable stage [2]. As in many other cancers, phenotypic and functional heterogeneity among cancer cells within the tumour make curing lung cancer difficult [4]. Controversies and uncertainties remain, and no consensus markers for lung CSCs have yet been identified [7]. This is most likely due to the heterogeneous origins and high plasticity of lung CSCs [8, 9]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call